Urology Textbook
Clinical Essentials
By Dirk Manski, MD

 You are here: Urology Textbook > Prostate > Prostate cancer > Staging

Prostate Cancer: Diagnosis and Staging


Guidelines and review literature: (EAU Guidelines Prostate Cancer) (S3-Leitlinie Prostatakarzinom) (Walsh-Campbell Urology).

Assessment of tumor stage and biological aggressiveness is crucial for treatment decisions in prostate cancer. Diagnostic evaluation includes digital rectal examination (DRE), PSA concentration, prostate biopsy histology, laboratory tests, imaging, and, in selected cases, pelvic lymphadenectomy.

Clinical Staging of Prostate Cancer

Digital rectal examination, PSA concentration, and Gleason grade each correlate well with the pathological tumor stage. However, the predictive accuracy of an individual parameter is too low for a given patient. Combining these variables allows reliable estimation of clinical risk (prostate cancer mortality) [Table D’Amico risk classification].

D’Amico risk classification for prostate cancer: clinical risk of mortality in localized prostate cancer before external beam radiotherapy and radical prostatectomy (D’Amico et al., 2003). (*) The figures represent prostate cancer-specific 10-year mortality in historical treatment groups with differing compositions. They indicate a risk-adapted trend in favor of radical prostatectomy but do not permit a direct comparison of effectiveness between EBRT and RPE.
RiskCriteria10-year mortality after EBRT (*)10-year mortality after RPE (*)
LowPSA < 10 ng/ml and Gleason score ≤ 62%1%
IntermediatePSA 10–20 ng/ml or Gleason score 78%4%
HighPSA > 20 ng/ml or Gleason score ≥ 824%11%

Additional consideration of tumor burden in the biopsy and other clinical parameters further improves predictive accuracy. The CAPRA score is suitable for this purpose [Table CAPRA score]. CAPRA stands for Cancer of the Prostate Risk Assessment and was developed at the University of California, San Francisco, using data from the CaPSURE study (Cooperberg et al., 2009). Table pathological outcomes and prognosis after radical prostatectomy shows the results according to the CAPRA score.

CAPRA score for determining clinical risk in prostate cancer (Cooperberg et al., 2009).
0–2 points: low risk.
3–5 points: intermediate risk.
6–10 points: high risk.
Risk factorCriteriaPoints
Age< 50 years0
≥ 50 years1
PSA at diagnosis≤ 6 ng/ml0
6.1–10 ng/ml1
10.1–20 ng/ml2
20.1–30 ng/ml3
> 30 ng/ml4
Biopsy Gleason scoreNo pattern 4 or 50
Secondary pattern 4 or 51
Primary pattern 4 or 53
Clinical stageT1–T20
≥ T3a1
Positive biopsy cores< 34%0
≥ 34%1

Pathological outcomes and progression-free survival after radical prostatectomy according to the CAPRA score (Cooperberg et al., 2009; Budäus et al., 2012). Data from the cited studies were rounded and expressed as ranges.
CAPRA score0–123456> 7
Positive surgical margin8–2415–2616–3118–4226–4444–5342–58
Extraprostatic extension6–1416–1923–2626–4044–5551–5668–86
Seminal vesicle invasion1–23–44–69–1113–212227–47
Lymph node metastases0–11–321–43–114–113–34
Progression-free at 3 years92–9584–9576–8773–8267–7046–7235–50
Progression-free at 5 years86–9175–9165–8360–7452–6129–6220–30

The Partin tables combine local tumor stage, PSA concentration, and Gleason score to estimate the risk of extraprostatic extension, seminal vesicle invasion, and lymph node metastases. Some authors consider that the tables underestimate lymph node metastasis risk because of the limited lymphadenectomy template used in the clinical series.

The Kattan nomograms of the Memorial Sloan Kettering Cancer Center likewise combine local tumor stage, PSA concentration, and Gleason score. They estimate 10-year progression-free survival after radical prostatectomy and 15-year cancer-specific survival.

Bone Scintigraphy

Bone scintigraphy is a conventional staging modality for bone metastases with relatively high sensitivity but limited specificity [Figure bone metastases in prostate cancer]. Indeterminate findings should be evaluated by MRI, CT, or conventional radiography according to their location and the clinical question; bone biopsy should be considered when uncertainty remains.

Bone scintigraphy should be omitted in patients with a PSA concentration below 10 ng/ml, Gleason score below 8, clinically localized disease, and no bone pain.

Bone scintigraphy in a patient with prostate cancer and a PSA concentration of 100 ng/ml: multiple suspicious lesions in the thoracic and lumbar spine, sacrum, and ribs. With kind permission, Dr. G. Antes, Kempten.
Bone scintigraphy with multiple suspicious lesions in the thoracic and lumbar spine, sacrum, and ribs in a patient with prostate cancer.

Computed Tomography

CT is indicated in advanced prostate cancer, either in combination with bone scintigraphy or as part of a PET/CT examination. CT can detect enlarged lymph nodes, bone metastases, hydronephrosis, and infiltration of adjacent organs. In asymptomatic patients with a PSA concentration below 20 ng/ml and a Gleason score below 8, treatment-relevant pathological findings are uncommon.

Positron Emission Tomography

The main indications for PSMA-PET/CT are high-risk prostate cancer, biochemical recurrence after curative treatment, and progression during systemic therapy for metastatic prostate cancer. PET combined with CT or MRI provides very high diagnostic accuracy and is superior to the combination of bone scintigraphy and CT (Bukavina et al., 2023). Tracers include 68Ga-PSMA and 18F-labeled PSMA ligands.

Multiparametric MRI of the Prostate

Multiparametric MRI of the prostate is indicated for imaging locally advanced prostate cancer when imaging findings may alter the treatment decision [Figure multiparametric MRI in pT3b prostate cancer].




Pelvic Lymphadenectomy

Pelvic lymphadenectomy is a surgical staging procedure when there is a relevant probability of lymph node metastases and is usually performed during radical prostatectomy. Historically, isolated surgical lymph node staging was discussed before perineal prostatectomy or brachytherapy; it is no longer routinely indicated. Indications and extent are discussed in the section on radical prostatectomy. See also laparoscopic pelvic lymphadenectomy for technique and complications.

Experimental Diagnostic Methods

New Screening or Tumor Markers

PCA3:

PCA3 (prostate cancer antigen 3) is a non-protein-coding RNA that is overexpressed in prostate cancer and can be detected in urine after prostatic massage. PCA3 may provide additional information in selected patients with an elevated PSA concentration and a previous negative biopsy, but it is not a standard test for population-based early detection.

Analysis of Gene Expression:

Tissue-based gene-expression and genomic-classifier tests, such as Prolaris, Decipher Prostate, or the Genomic Prostate Score, may provide additional prognostic information in selected patients with localized prostate cancer. They are used mainly to estimate tumor aggressiveness and to support treatment decisions, for example active surveillance versus curative treatment. Routine use is not recommended.

Other Methods:

Other experimental approaches include detection of micrometastases in bone marrow and RT-PCR for detecting prostate cancer cells in blood or lymph nodes.

Imaging

New methods, including PET, MRI with specialized contrast agents, and specialized ultrasound techniques, are being evaluated in clinical series.

Micro-ultrasound:

Targeted prostate biopsy using a high-resolution TRUS probe (ExactVu, 29 MHz) may support detection of clinically significant prostate cancer (Dariane et al., 2022). The method is promising but does not currently replace guideline-based mpMRI-guided and systematic diagnostic evaluation.

Elastography:

Ultrasound elastography displays the elasticity of prostate tissue in color by applying pressure with an ultrasound probe. Less elastic regions are suspicious for cancer. However, sensitivity and specificity are insufficient to omit systematic or mpMRI-targeted prostate biopsy.

Analysis of Ultrasonography Raw Data:

Database-assisted analysis of ultrasound raw data, such as HistoScanning, was developed to improve prostate cancer detection. Independent studies have not demonstrated sufficient sensitivity and specificity for routine clinical use.






Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Afshar-Oromieh, A.; Haberkorn, U.; Schlemmer, H. P.; Fenchel, M.; Eder, M.; Eisenhut, M.; Hadaschik, B. A.; Kopp-Schneider, A. & Röthke, M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
Eur J Nucl Med Mol Imaging, 2014, 41, 887-897

Auprich, M.; Bjartell, A.; Chun, F. K.; de la Taille, A.; Freedland, S. J.; Haese, A.; Schalken, J.; Stenzl, A.; Tombal, B. & van der Poel, H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Eur Urol, 2011, 60, 1045-1054.

Brock, M.; von Bodman, C.; Palisaar, R. J.; Löppenberg, B.; Sommerer, F.; Deix, T.; Noldus, J. & Eggert, T. The Impact of Real-Time Elastography Guiding a Systematic Prostate Biopsy to Improve Cancer Detection Rate: A Prospective Study of 353 Patients.
J Urol, 2012.

D'Amico, A. V.; Moul, J.; Carroll, P. R.; Sun, L.; Lubeck, D. & Chen, M. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
J Clin Oncol, 2003, 21, 2163-2172.

D'Amico, A. V.; Hui-Chen, M.; Renshaw, A. A.; Sussman, B.; Roehl, K. A. & Catalona, W. J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
J Urol, 2006, 176, S11-S15.

Guidelines on Prostate Cancer of the European Association of Urology (EAU), https://uroweb.org/guidelines/prostate-cancer/.

Harisinghani u.a. 2003 HARISINGHANI, M. G. ; BARENTSZ, J. ; HAHN, P. F. ; DESERNO, W. M. ; TABATABAEI, S. ; KAA, C. H. van de ; ROSETTE, J. de la ; WEISSLEDER, R.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
In: N Engl J Med
348 (2003), Nr. 25, S. 2491–9

Javed, S.; Chadwick, E.; Edwards, A. A.; Beveridge, S.; Laing, R.; Bott, S.; Eden, C. & Langley, S. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies.
BJU Int, 2014, 114, 541-548

Kattan u.a. 1998 KATTAN, M. W. ; EASTHAM, J. A. ; STAPLETON, A. M. ; WHEELER, T. M. ; SCARDINO, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
In: J Natl Cancer Inst
90 (1998), Nr. 10, S. 766–71

Kattan u.a. 2001 KATTAN, M. W. ; POTTERS, L. ; BLASKO, J. C. ; BEYER, D. C. ; FEARN, P. ; CAVANAGH, W. ; LEIBEL, S. ; SCARDINO, P. T.: Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer.
In: Urology
58 (2001), Nr. 3, S. 393–9

Kattan u.a. 2003 KATTAN, M. W. ; ZELEFSKY, M. J. ; KUPELIAN, P. A. ; CHO, D. ; SCARDINO, P. T. ; FUKS, Z. ; LEIBEL, S. A.: Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.
In: J Clin Oncol
21 (2003), Nr. 24, S. 4568–71

Perdonà, S.; Cavadas, V.; Lorenzo, G. D.; Damiano, R.; Chiappetta, G.; Prete, P. D.; Franco, R.; Azzarito, G.; Scala, S.; Arra, C.; Sio, M. D. & Autorino, R. Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3.
Eur Urol, 2010

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom

Wein, A. J.; Kavoussi, L. R.; Partin, A. P. & Peters, C. A. Campbell-Walsh Urology
. Elsevier, 2015. ISBN 978-1455775675.

Sanz u.a. 2004 SANZ, G. ; RIOJA, J. ; ZUDAIRE, J. J. ; BERIAN, J. M. ; RICHTER, J. A.: PET and prostate cancer.
In: World J Urol
22 (2004), Nr. 5, S. 351–2

Schiffmann, J.; Tennstedt, P.; Fischer, J.; Tian, Z.; Beyer, B.; Boehm, K.; Sun, M.; Gandaglia, G.; Michl, U.; Graefen, M. & Salomon, G. Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate.
World J Urol, 2014, 32, 925-930.

Smaletz u.a. 2002 SMALETZ, O. ; SCHER, H. I. ; SMALL, E. J. ; VERBEL, D. A. ; MCMILLAN, A. ; REGAN, K. ; KELLY, W. K. ; KATTAN, M. W.: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.
In: J Clin Oncol
20 (2002), Nr. 19, S. 3972–82

Wawroschek u.a. 2003 WAWROSCHEK, Friedhelm ; WAGNER, Theodor ; HAMM, Michael ; WECKERMANN, Dorothea ; VOGT, Harry ; MäRKL, Bruno ; GORDIJN, Ronald ; HARZMANN, Rolf: The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer.
In: Eur Urol
43 (2003), Feb, Nr. 2, S. 132–6; discussion 137



  Deutsche Version: Prostatakarzinom

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.